Trial Profile
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 02 Dec 2022 Planned End Date changed from 31 Jul 2026 to 31 Dec 2027.
- 02 Dec 2022 Planned primary completion date changed from 31 Jan 2024 to 31 Mar 2024.